SYNLAB UK & Ireland:

Modern Slavery & Human Trafficking Statement 2020

Published: 26th January 2020

This is the SYNLAB Group’s Modern Slavery and Human Trafficking Statement under Section 54 of the UK Modern Slavery Act 2015 (MSA) for the financial year 2019. It applies to all Group companies which are regulated under the MSA. Modern slavery is a broad term that encompasses slavery, servitude, forced and compulsory labour and human trafficking. Subsequently, the SYNLAB Group is committed to ensuring that the supply chains of its subsidiaries and their business activities are free from ethical and labour standards abuse. This statement summarises the measures that the SYNLAB Group has taken to assess and address the risk of modern slavery in its business and supply chains.

Our Organisational Structure, Business Model & Supply Chain

SYNLAB Limited is the ultimate parent company of all the subsidiaries that belong to the SYNLAB Group of companies (SYNLAB). SYNLAB Limited provides head office support activities to its subsidiaries by way of proving guidelines, advice and assistance. Trading within the UK, SYNLAB has two subsidiaries which meet the reporting requirements of the UK Modern Slavery Act: SYNLAB Bondco PLC is a non-operational debt issuing vehicle, proving financing to the SYNLAB Group; and Labco UK Group Limited carries out the majority of our operating business activities within the UK.

We are an international diagnostic service provider. We provide analytical, diagnostical and pathological services in the field of human and veterinary medicine diagnostic, hygiene analyses, environmental analysis, as well as laboratory services to the pharma and food sector, and related products. We offer our services in more than 40 countries in four continents (Europe, Latin America, Africa and Middle East/Asia), having more than 20,000 employees (Members).

In providing our services, we rely on the supply of technical equipment provided by suppliers of analytical machinery and technology for laboratory analysis/diagnostic testing, as well as regents and chemicals utilized in such testing. Goods and services are provided by professional services companies as well as subcontractors including couriers and sub-processors of test samples. In addition, we rely on external professional services providers in relation to our head office support, including financing related activities as well as corporate and financial housekeeping.

Our Policies

We have adopted a Code of Conduct, setting out our commitment to act ethically and with integrity in all our business relationships. The Code of Conduct is currently being implemented within our Group and our Members receive training on it alongside the rollout. In addition, our UK entities have adopted a dedicated policy on anti-slavery and human trafficking. All our members must comply with all relevant laws and regulations (Including those on modern slavery and human trafficking) and they must respect the personal dignity, rights and diversity of everyone within and outside SYNLAB. We support all our Group companies with a view to ensure compliance with our Code of Conduct.


To ensure a high level of understanding of the risks of modern slavery and human trafficking in our supply chains and our business, we provide training to our Members.

Due Diligence & Risk Assessment

We acknowledge that slavery and human trafficking exist in many jurisdictions in which we operate, and/or from which we procure goods or services. Our overall objective is to establish and maintain relationships with our suppliers that will minimise the risk that slavery or human trafficking could occur within our supply chains.

Our due diligence approach is based on inclusion of our relevant functional teams, such as legal, compliance, M&A, human resources and procurement. We continuing to invest in tackling modern slavery by implementing various instruments, including the introduction of MSA provisions in our supplier contracts and the circulation of supplier assessment questionnaires.

To mitigate against the risk of modern slavery and human trafficking in our supply chains, risk assessment and due diligence will continue to focus on our first-tier supplier relationships. It is understood that we need to refine our risk assessments in accordance of our findings. We are taking steps to establish frameworks in which all elements of our supply chain are expected to observe applicable laws and operate in accordance with our Code of Conduct.

We have a dedicated Compliance Committee, which consists of the Group Chief Executive Officer and Chief Financial Officer, chaired by the Group Chief Compliance Officer. The Compliance Committee is supported by Regional Compliance Officers, submitting regular reports to the Office of the Group Chief Compliance Officer on compliance findings.

Effective Actions Taken

We use the following key performance indicators to measure how effective we have been to ensure that slavery and human trafficking is not taking place in any part of our business or supply chain:

  • Anti-slavery and human trafficking clauses: We included an anti-slavery and human trafficking clause in our procurement templates. In addition, we are amending existing procurement contracts of our top global first tier supplier to confirm MSA compliance within our supply chain.
  • Training our Members: We carried out modern slavery and human trafficking training and workshops for the all vast majority of our Members in the UK and the most relevant Members of Group HR and Group Legal.
  • Compliance reporting: In 2019, no compliance findings on modern slavery and human trafficking were reported by the Regional Compliance Officers.
Looking Ahead

We understand that combating modern slavery and human trafficking is an ongoing imperative. In 2020, we will continue to invest in doing so. Our actions will comprise:

  • CEO Message: Our regular CEO message to our Members will emphasise on our social responsibly and ethical principles, including our rigorous standing against modern slavery and human trafficking.
  • Policies: We plan to implement a dedicated policy on anti-slavery and human trafficking / human rights.
  • Human Resources: We will improve transparency in our recruitment processes, and compliance with vetting standards for our Members and contingent labour.
  • Training for our Members: We will continue to raise awareness on modern slavery and human trafficking among our Members. We will continue to train our Members in 2020, focusing on Procurement, Operations, Facility Management and Finance.
  • Supplier Questionnaire: We will continue to issue our supplier questionnaire to our suppliers, continuing to ensure that our supply chain complies with our ethical standards set out in our Code of Conduct.

Mathieu Floreani

CEO & member of the Board of Directors for SYNLAB Ltd.

For our 2019 Modern Slavery and Human Trafficking Statement please click here.

Latest SYNLAB UK & Ireland News
SYNLAB sets its Sights on Becoming the UK’s Leading Laboratory Diagnostics Organisation

Published: 23rd August 2023 Science for Life, Health and Wellbeing SYNLAB, the medical diagnostics provider, has set out its ambition to become the UK’s leading …

Read More (about 'SYNLAB sets its Sights on Becoming the UK’s Leading Laboratory Diagnostics Organisation')
Modern Slavery & Human Trafficking Statement 2023

Published: 11th July 2023 INTRODUCTION This is SYNLAB UK and Ireland’s (SYNLAB UK&I) Modern Slavery and Human Trafficking Statement under Section 54 of the UK…

Read More (about 'Modern Slavery & Human Trafficking Statement 2023')
Exceptional talent honoured during SYNLAB awards programme

Published: 8th December 2022 SYNLAB’s 2022 Excellence Awards recognised individuals and teams from across its UK & Ireland services, who display outstanding service in their…

Read More (about 'Exceptional talent honoured during SYNLAB awards programme')
SYNLAB Primed to Help Steer NHS’s COVID Bounce Back

Published: 13th October 2022 SYNLAB is ready to play a key role in assisting the UK’s ongoing COVID recovery after securing membership of NHS England’s…

Read More (about 'SYNLAB Primed to Help Steer NHS’s COVID Bounce Back')
Landmark Day for Pathology Partnership with Launch of Synnovis Brand

Published: 4th October 2022 A pathology partnership performing 32 million tests a year has been relaunched as ‘Synnovis’ – officially heralding the start of a…

Read More (about 'Landmark Day for Pathology Partnership with Launch of Synnovis Brand')
Pathology laboratory becomes the first in the UK to support remote plate reading  

Published: 15th June 2022 A pathology laboratory is leading the way in speeding up access to patient care and treatment after becoming the first in…

Read More (about 'Pathology laboratory becomes the first in the UK to support remote plate reading  ')
SYNLAB ESG Roadmap and Framework

Published: 17th May 2022 Introduction SYNLAB UK&I is thrilled to publish its UK&I ESG Framework and Roadmap, which outlines out how we will achieve our…

Read More (about 'SYNLAB ESG Roadmap and Framework')
GENDER Pay Gap Report 2020-21

Published: 21st September 2021 A Message From Our CEO Whilst we are pleased at the improvement in our gender pay gap over the past four…

Read More (about 'GENDER Pay Gap Report 2020-21')
SYNLAB Goes Public

Published: 30th April 2021 We are proud to announce that SYNLAB is now listed on the Frankfurt Stock Exchange. This historical milestone is built on…

Read More (about 'SYNLAB Goes Public')